TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25498055
Drug: Steroid-free immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-free immunosuppression (group B)
Study: 25498055
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy once daily (group C)
Study: 22513495
Drug: 10-session behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-session behavioral treatment
Study: 18511542
Drug: Minocycline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline treatment associated with lid hygiene
Study: 10691818
Drug: L-arginine (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (2.4 g/day)
Study: 9432686
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by concurrent chemoradiotherapy and definitive surgery
Study: 9432686
Drug: Upfront surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upfront surgery followed by adjuvant radiation therapy
Study: 9432686
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by definitive concurrent chemoradiation up to 65 Gy radiation dose
Study: 1302807
Drug: Single-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oral fluconazole (150 mg)
Study: 1302807
Drug: Three-day local
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day local treatment with miconazole pessaries
Study: 3895875
Drug: Lidocaine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (300 mg intramuscularly followed by 100 mg intravenously)
Study: 27703240
Drug: BK-SE36 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BK-SE36 vaccine
Study: 9493256
Drug: Repeated measures
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated measures of weight loss, drug plasma level, and pill count data
Study: 7931890
Drug: High-dose, short-duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose, short-duration ribavirin aerosol therapy (6 gm/100 ml water for 2 hours three times a day)
Study: 7931890
Drug: Standard ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard ribavirin aerosol therapy (6 gm/300 ml water for 18 hours daily)
Study: 26183686
Drug: Piragliatin 200
Normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piragliatin 200 mg BID
Study: 23739279
Drug: solution (N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution (N-acetylcysteine and simethicone)
Study: 23739279
Drug: water control
Approvals — FDA: no, EMA: no, PMDA: no
Description: water control (100 ml sterile water)
Study: 20562781
Drug: Individualized dose
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized dose regimen of amitriptyline (n=30)
Study: 20562781
Drug: Empiric dose
Normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric dose regimen of amitriptyline (n=30)
Study: 17356528
Drug: Sibutramine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (15 mg/day)
Study: 10201469
Drug: Hydrocortisone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (100 mg by i.v. infusion immediately before endoscopy)
Study: 10201469
Drug: Placebo (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sodium chloride administered in the same fashion)
Study: 7773086
Drug: Bisoprolol, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol, 10 mg once a day
Study: 7773086
Drug: Propranolol, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 80 mg twice a day
Study: 7773086
Drug: Metoprolol, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol, 100 mg twice a day
Study: 2090533
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg once a day)
Study: 376355
Drug: Danazol 200
Normalized name: danazol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol 200 mg daily for 100 days
Study: 29945169
Drug: P27A antigen
Normalized name: TRICOPHYTON ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: P27A antigen (10 or 50 μg) with Alhydrogel or GLA-SE (2.5 or 5 μg)
Study: 29945169
Drug: Control rabies
Normalized name: rabies virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control rabies vaccine (Verorab)
Study: 28176150
Drug: Daily monetary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily monetary incentives
Study: 28176150
Drug: Daily incentive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily incentive condition
Study: 25882659
Drug: Active PEMF
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active PEMF therapy (60 minutes; frequency: 12 Hz; intensity: 12 Gauss)
Study: 21855759
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of betamethasone acetate 5.7 mg/mL (Group 1)
Study: 19074930
Drug: Effective CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective CPAP therapy
Study: 17318417
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rHu‐EPO) at doses of 20, 40, 60, 90, 120, and 160 kIU
Study: 15260961
Drug: Oral dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dextroamphetamine (AMPH, 0.25 mg/kg)
Study: 12108616
Drug: Intravenous porcine
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous porcine secretin
Study: 3094059
Drug: Methylphenidate (0.65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.65 mg/kg)
Study: 30499799
Drug: Negative Pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative Pressure Wound Therapy (NPWT) among patients receiving a stoma
Study: 28830411
Drug: Moringa oleifera
Normalized name: Moringa Oleifera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moringa oleifera (M.O.) Lam. leaf powder supplementation (daily for 6 months)
Study: 23632235
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (CLA) supplementation, 3 g CLA/d for 6 weeks
Study: 21590648
Drug: Pioglitazone (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (titrated to 45 mg/day)
Study: 21590648
Drug: Glibenclamide (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (titrated to 15 mg/day)
Study: 17053155
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (1296 mg EPA + 864 mg DHA/day) for 8 weeks
Study: 17053155
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil supplementation (3510 mg alpha-linolenic acid + 900 mg linoleic acid/day) for 8 weeks
Study: 9278195
Drug: Neoral (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral (5 mg kg(‐1) dose)
Study: 9278195
Drug: CsA capsules
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA capsules (5 mg kg(‐1) dose)
Study: 1329172
Drug: Group sequential
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group sequential method for determining study duration in clinical trials
Study: 1544695
Drug: Tamoxifen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (30 mg daily)
Study: 3978249
Drug: Tamoxifen plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen plus nandrolone decanoate (100 mg i.m. once a week for four weeks, then every other week)
Study: 21474675
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HDM) 5 g/m² as a 24-hour infusion at weeks 4, 7, 10, and 13
Study: 21474675
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HDM)
Study: 21474675
Drug: No high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: No high-dose methotrexate (no HDM)
Study: 16492230
Drug: Sumatriptan NS
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan NS 5 mg
Study: 15969863
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa treatment
Study: 14556671
Drug: Delayed epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed epoetin alfa treatment
Study: 9100722
Drug: Advance directives
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advance directives with specific instructions to forgo life-sustaining treatment
Study: 27904951
Drug: Peri-articular multimodal
Normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-articular multimodal drug injection (bupivacaine hydrochloride, morphine sulphate, epinephrine, and ketorolac)
Study: 27904951
Drug: Peri-articular multimodal
Normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-articular multimodal drug injection
Study: 24965797
Drug: Trauma-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused cognitive behavioral therapy (TF-CBT)
Study: 21928867
Drug: Treatment entry
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment entry
Study: 2895840
Drug: During treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: During treatment
Study: 19330295
Drug: Concurrent radiochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent radiochemotherapy (RTCT) with cisplatin 20 mg/m(2) x 5 days
Study: 8914115
Drug: Placebo nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nicotine patch
Study: 9579151
Drug: L-tyrosine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tyrosine (100 mg/kg body weight/d)
Study: 9579151
Drug: L-alanine (placebo)
Normalized name: L-alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-alanine (placebo)
Study: 7543651
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of porcine galanin 500 micrograms in 100 mL saline
Study: 7543651
Drug: IV injection
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection of GHRH (1-29)NH2 1 microgram/kg plus GnRH 100 micrograms at time 0 plus IV infusion of porcine galanin 500 micrograms in 100 mL saline from -10 to +30 minutes
Study: 2615925
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg WEB 1881 FU
Study: 2615925
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg WEB 1881 FU
Study: 29783025
Drug: High-dose trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose trivalent inactivated influenza vaccine (HDTIV)
Study: 20869984
Drug: Maintenance-tailored therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance-tailored therapy (MTT)
Study: 20869984
Drug: Standard behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard behavior therapy (SBT)
Study: 16929238
Drug: Chilli diet
Normalized name: Chilli pepper
DrugBank: Capsicum (DB10897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chilli diet (30 g/day of a chilli blend with 55% cayenne chilli)
Study: 9631311
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg daily and amoxicillin 500 mg three times a day for 14 days (LA)
Study: 9631311
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg daily and amoxicillin 500 mg three times a day for 14 days plus miconazole gel 100 mg three times a day for 14 days (LAM)
Study: 3244616
Drug: Heidelberg capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heidelberg capsule (HC) ingestion after a standardized 500-kcal breakfast in males
Study: 3244616
Drug: Heidelberg capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heidelberg capsule (HC) ingestion in supine posture
Study: 3244616
Drug: Heidelberg capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heidelberg capsule (HC) ingestion in elderly males (greater than 65 years)
Study: 28969659
Drug: Azithromycin 20
Normalized name: azithromycin 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 20 mg/kg/day (maximum 1000 mg/day) in a single daily dose
Study: 28969659
Drug: Co-trimoxazole 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole 60 mg/kg/day (maximum 3000 mg/day) in two divided doses
Study: 26585952
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (1200 IU daily)
Study: 24499609
Drug: SBIRT intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SBIRT intervention for low or medium risk offenders, including brief intervention and referral to community treatment for high risk offenders.
Study: 22031659
Drug: Low-dose plant-derived
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose plant-derived (n-3) fatty acids (2.2 g/d α-linolenic acid)
Study: 22031659
Drug: High-dose plant-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose plant-derived (n-3) fatty acids (6.6 g/d α-linolenic acid)
Study: 22031659
Drug: Low-dose marine-derived
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose marine-derived (n-3) fatty acids (1.2 g/d EPA and DHA)
Study: 22031659
Drug: High-dose marine-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose marine-derived (n-3) fatty acids (3.6 g/d EPA and DHA)
Study: 18652090
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment followed by adenotonsillectomy
Study: 18652090
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies (adenotonsillectomy and orthodontic expansion)
Study: 16410460
Drug: rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone (4 mg BID)
Study: 12612145
Drug: Diet A
Normalized name: Diet Aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet A (24 mg Met/(kg. d) and no Cys)
Study: 12612145
Drug: Diet B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet B (13 mg Met/(kg. d) and 11 mg Cys/(kg. d))
Study: 12612145
Drug: Diet C
Normalized name: Diet Caplets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet C (5 mg Met/(kg. d) and 19 mg Cys/(kg. d))
Study: 10905679
Drug: Ceftriaxone antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone antibiotic prophylaxis
Study: 2853038
Drug: Melatonin 1
Normalized name: melatonin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 1 mg
Study: 7871062
Drug: Melatonin 40
Normalized name: vit B/folic acid/calcium/soy xt/black cohosh xt/melatonin 400 mcg-125 mg-62 mg-40 mg (day)/175 mg-62 mg-1 mg (night) ORAL CAPSULE, SEQUENTIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 40 mg
Study: 2514318
Drug: rt‐PA (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt‐PA (60 mg over 90 minutes i.v.)
Study: 19405832
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (delayed treatment for 3 months)
Study: 17078435
Drug: Electrical acupuncture
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrical acupuncture and auricular-plaster therapy
Study: 25127090
Drug: Oral hydrocortisone
Normalized name: hydrocortisone Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydrocortisone
Study: 14700452
Drug: Venlafaxine extended-release
Normalized name: Desvenlafaxine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine extended-release (XR)
Study: 11207517
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg b.d. (OABC group)
Study: 11207517
Drug: Furazolidone 200
Normalized name: furazolidone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furazolidone 200 mg b.d. (OABF group)
Study: 7180724
Drug: Active diuretic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active diuretic therapy
Study: 26458907
Drug: Oropharyngeal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal administration of mother's milk (0.2 mL every 2 hours for 48 hours, then every 3 hours until 32 weeks corrected-gestational age)
Study: 26458907
Drug: Placebo (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.2 mL sterile water every 2 hours for 48 hours, then every 3 hours until 32 weeks corrected-gestational age)
Study: 21332400
Drug: STPG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: STPG treatment (4 capsules, 2g)
Study: 19541291
Drug: Lutein, zeaxanthin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein, zeaxanthin and blackcurrant extract (LUT) supplement
Study: 9608790
Drug: Bupivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine + lidocaine (30 mg of bupivacaine plus 240 mg of lidocaine)
Study: 9608790
Drug: Lidocaine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (300 mg)
Study: 27541827
Drug: 6 monoclonal
Normalized name: HUMAN ANTI-IL-6 MONOCLONAL ANTIBODY (PF-04236921)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 monoclonal antibodies (SP142, E1L3N, 9A11, SP263, 22c3, and 28-8)
Study: 26437899
Drug: Essential amino
Normalized name: Essential amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential amino acids (EAAs) 8 g/d
Study: 24798153
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 500 mg/d
Study: 20579849
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 100 mg/d
Study: 3752418
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of birch pollen preparation (n = 11)
Study: 24084157
Drug: Estimated albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estimated albumin excretion rate (eAER)
Study: 11222362
Drug: Asparaginase treatment
Normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asparaginase treatment duration (at least 26 weeks)
Study: 9555799
Drug: High-dose UVA1
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose UVA1 phototherapy (UVA1R; 10 days, 130 J/cm2/day; n = 20)
Study: 9555799
Drug: Topical fluocortolone
Normalized name: fluocortolone Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluocortolone (10 days, 1 x daily; n = 17)
Study: 9555799
Drug: UVA-UVB therapy
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA-UVB therapy (10 days, 1 x daily, minimal erythema dose-dependent; n = 16)
Study: 2903322
Drug: Tamoxifen (TM),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (TM), 30 mg daily for 2 years
Study: 6121545
Drug: Naloxone hydrochloride
Normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone hydrochloride administration in neuroleptic-treated schizophrenics
Study: 6121545
Drug: Naloxone hydrochloride
Normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone hydrochloride administration in total schizophrenic population
Study: 6121545
Drug: Naloxone hydrochloride
Normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone hydrochloride administration in manic patients
Study: 28096659
Drug: Ponesimod (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponesimod (10 mg, 20 mg, and 40 mg each consecutively for 3 days)
Study: 18540781
Drug: Olanzapine 2.5
Normalized name: olanzapine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 2.5 mg
Study: 24700260
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (deep breaths)
Study: 22692271
Drug: AmF/SnF2 toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmF/SnF2 toothpaste twice daily for three minutes and AmF/SnF2 mouthrinse for 30 seconds
Study: 22692271
Drug: AmF/SnF2 toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmF/SnF2 toothpaste twice daily for three minutes
Study: 19631850
Drug: Non-surgical endodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical endodontic treatment
Study: 15224028
Drug: N-acetylcysteine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (100 mg/kg into cardiopulmonary bypass prime followed by infusion at 20 mg.kg(‐1).h(‐1); n = 18)
Study: 8026205
Drug: Continuous postural
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous postural therapy on an oscillating bed
Study: 2690332
Drug: Omeprazole, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 30 mg once daily
Study: 2690332
Drug: Cimetidine, 200
Normalized name: Cimetidine, 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 200 mg t.d.s. and 400 mg at bedtime
Study: 1015496
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of metoclopramide intravenously
Study: 17483854
Drug: Care recipients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care recipients take medicines that affect the central nervous system or stomach
Study: 15454833
Drug: MSC (Avemar)
Normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSC (Avemar) with cytotoxic drugs
Study: 15454833
Drug: Control (cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (cytotoxic drugs without MSC)
Study: 29462266
Drug: Rifampin 600
Normalized name: rifampin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg once daily for 5 days